argenx SE has achieved a dramatic financial inflection, with Q2 2026 revenue surging 197% year-over-year to $2.8 billion, driven by the rapid global adoption of VYVGART.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has accelerated to 197% year-over-year in Q2 2026, driving gross margins to a best-in-class 90.1% and operating margins to 30.1%, demonstrating powerful operating leverage as the commercial model scales.
VYVGART generated over $4.1 billion in 2025, nearly doubling year-on-year, showcasing strong revenue growth.
New clinical data presented at the 2026 American Academy of Neurology meeting demonstrated VYVGART's efficacy in treating ocular myasthenia gravis and broader MG subtypes.
argenx SE operates in key international markets including the United States, Japan, China, and the Netherlands, enhancing its revenue potential.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $7.80+4.8% vs $7.44 | $2.8B+69.6% vs $1.7B |
Q2 2026 May 7, 2026 | $5.90+14.3% vs $5.16 | $3.2B+121.8% vs $1.4B |
Q1 2026 Feb 26, 2026 | $8.02+48.2% vs $5.41 | $2.4B+79.6% vs $1.3B |
Q4 2025 Oct 30, 2025 | $5.18+18.5% vs $4.37 | $948M-25.7% vs $1.3B |
Investors should consider buying resurgent healthcare and biotech stocks amid the AI selloff. Today, we are digging into why it might be time to buy biopharmaceutical stock Argenx (ARGX).
November 3, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor conferences in November: Guggenheim 3rd Annual Healthcare Innovation Conference. Fireside chat on Tuesday, November 10 at 2:00 p.m.
Product net sales reached $1.7 billion, growing 54% year over year. Operating profit reached $486 million with a 28% operating margin.
Diversify Advisory Services LLC lifted its position in shares of argenex SE (NASDAQ: ARGX) by 32.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,911 shares of the company's stock after purchasing an additional 714 shares during the period. Diversify Advisory
Benchmark ARGX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for argenx SE (ARGX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $927.21 | $60.16B | 47.23 | 89.64% | 31.11% | 20.15% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $155.94 | $20.82B | 7.90 | 65.19% | 54.34% | 159.72% | — | |
| $17.82 | $1.88B | 127.93 | 15.58% | 0.75% | 1.04% | — | |
| $56.03 | $10.83B | -567.68 | 12.87% | -0.52% | -0.31% | — | |
| $39.42 | $6.55B | -11.55 | 33.87% | -64.64% | -110.84% | — |
argenx SE (ARGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ARGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
argenx SE (ARGX) stock FAQ — growth, dividends, profitability & financials explained
argenx SE (ARGX) reported $4.15B in revenue in fiscal year 2025. That is 284775% more than the $1.5M of fiscal year 2011.
argenx SE (ARGX) grew revenue by 89.6% in fiscal year 2025, compared with the prior fiscal year.
Yes. argenx SE (ARGX) earned $1.29B in net income in fiscal year 2025 (a 31.1% net margin).
argenx SE (ARGX) had a return on equity (ROE) of 20.2% in fiscal year 2025. That is well above the market's typical 10-15%.
argenx SE (ARGX) generated $844.3M in free cash flow in fiscal year 2025.
